Want to see KR:092730 full AI Analyst Report?
Top Page
NeoPharm Co., Ltd.
(092730)
Select Model
Select Model
Rating:82Outperform
Price Target:
₩25,868.00
Action:N/A
Date:10/28/26
The score is driven primarily by strong financial performance (high profitability and very low leverage) and favorable valuation (low P/E and high dividend yield). Technical indicators are the main offset, showing near-term weakness versus short-term moving averages and only neutral momentum readings.
Positive Factors
Revenue and earnings growth
Accelerating revenue accompanied by higher earnings indicates that NeoPharm is converting stronger demand into bottom-line growth. If this performance continues, the company should have greater capacity to reinvest in product development, expand commercialization, and strengthen its competitive position over the next several quarters.
Negative Factors
Margin compression
The decline in operating and cash earnings margins suggests that recent growth has not fully translated into expanding profitability. If margin pressure persists as revenue growth normalizes, earnings could grow more slowly and the company may have less internal cash available for development and commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and earnings growth
Accelerating revenue accompanied by higher earnings indicates that NeoPharm is converting stronger demand into bottom-line growth. If this performance continues, the company should have greater capacity to reinvest in product development, expand commercialization, and strengthen its competitive position over the next several quarters.
Read all positive factors
NeoPharm Co., Ltd. (092730) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩348.80B
Dividend Yield5.33%
Average Volume (3M)41.27K
Price to Earnings (P/E)6.1
Beta (1Y)0.09
Revenue Growth19.89%
EPS Growth21.27%
CountryKR
Employees141
SectorGeneral
Sector StrengthN/A
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)1873.90
Shares Outstanding16,027,988
10 Day Avg. Volume39,277
30 Day Avg. Volume41,266
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)0.93
Price to Sales (P/S)1.38
P/FCF Ratio6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2,013
Revenue Forecast (FY)₩168.00B
NeoPharm Co., Ltd. Business Overview & Revenue Model
Company Description
NeoPharm Co., Ltd. focuses on the invention, manufacturing, and distribution of various cosmetic, medical, and health-related goods. Their product line features advanced emulsified and specialized skincare solutions, particularly designed for indi...
NeoPharm Co., Ltd. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
94
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 136.80B | 132.18B | 119.01B | 97.10B | 85.03B | 87.93B |
| Gross Profit | 68.27B | 84.71B | 74.03B | 65.39B | 58.38B | 62.39B |
| EBITDA | 32.14B | 31.88B | 33.40B | 31.01B | 24.95B | 25.37B |
| Net Income | 29.31B | 27.82B | 23.06B | 23.21B | 17.03B | 17.71B |
Balance Sheet | ||||||
| Total Assets | 225.35B | 220.28B | 192.44B | 177.46B | 155.35B | 143.41B |
| Cash, Cash Equivalents and Short-Term Investments | 147.59B | 141.74B | 126.52B | 111.99B | 113.49B | 105.05B |
| Total Debt | 1.65B | 1.92B | 629.40M | 1.07B | 412.16M | 558.77M |
| Total Liabilities | 33.24B | 24.92B | 15.56B | 17.43B | 13.14B | 13.10B |
| Stockholders Equity | 192.11B | 195.36B | 176.88B | 160.03B | 142.21B | 130.30B |
Cash Flow | ||||||
| Free Cash Flow | 23.47B | 27.23B | 15.55B | 2.43B | 17.35B | 21.20B |
| Operating Cash Flow | 24.68B | 28.41B | 18.63B | 23.26B | 18.16B | 21.68B |
| Investing Cash Flow | -8.50B | -9.60B | -6.22B | -16.35B | -8.80B | -16.69B |
| Financing Cash Flow | -10.27B | -10.18B | -6.50B | -5.92B | -5.75B | -9.52B |
NeoPharm Co., Ltd. Technical Analysis
Negative
―
Price Trends
22953.00
Negative
20918.40
Positive
19718.60
Positive
Market Momentum
-126.96
Positive
47.06
Neutral
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:092730, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 22817.50, equal to the 50-day MA of 22953.00, and equal to the 200-day MA of 19718.60, indicating a neutral trend. The MACD of -126.96 indicates Positive momentum. The RSI at 47.06 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:092730.
NeoPharm Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | ₩348.80B | 6.12 | ― | 5.33% | 19.89% | 21.27% | |
70 Outperform | ₩245.83B | 10.28 | ― | 4.63% | -7.25% | 63.69% | |
65 Neutral | ₩217.37B | 3.92 | ― | 3.43% | 25.12% | 295.70% | |
60 Neutral | ₩261.75B | 15.14 | ― | 1.92% | 4.00% | -46.33% | |
60 Neutral | ₩2.81T | 14.64 | ― | 1.33% | 15.81% | 197.32% | |
56 Neutral | ₩2.72T | 14.72 | ― | 0.75% | 12.57% | 90.44% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
KR:092730
NeoPharm Co., Ltd.
22,300.00
5,524.08
32.93%
KR:018250
Aekyung Industrial Co., Ltd.
10,390.00
-3,644.12
-25.97%
KR:044820
Cosmax BTI Inc.
22,750.00
9,081.84
66.45%
KR:078520
Able C&C Co Ltd
9,960.00
400.81
4.19%
KR:161890
KOLMAR KOREA CO. LTD
115,300.00
39,729.27
52.57%
KR:192820
COSMAX, Inc.
248,000.00
49,251.70
24.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.